Keyphrases
Acute Lymphoblastic Leukemia
93%
Pediatric Acute Lymphoblastic Leukemia
29%
L-asparaginase
27%
Childhood Acute Lymphoblastic Leukemia
26%
Pediatric
21%
Dutch
20%
Minimal Residual Disease
19%
Leukemia Patients
18%
Pediatric Patients
17%
Netherlands
16%
KMT2A
15%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
15%
Children with Cancer
13%
Methotrexate
13%
Leukemia
13%
Childhood Cancer
11%
Oncology
11%
Event-free Survival
11%
BCP-ALL
10%
Pediatric Oncology
10%
Infant Acute Lymphoblastic Leukemia
9%
Pediatric Leukemia
9%
Vincristine-induced Peripheral Neuropathy
9%
IKZF1 Deletion
9%
Confidence Interval
9%
IKZF1
9%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
8%
Acute Myeloid Leukemia
8%
Overall Survival
8%
Media Risk
8%
High Risk
8%
International Consensus
7%
Pegaspargase
7%
Acute Lymphoblastic Leukemia Cells
7%
ETV6-RUNX1
7%
Escherichia Coli
6%
Young Adolescents
6%
Quality of Survival
6%
Oral mucositis
6%
Pharmacokinetics
6%
Measuring Quality
6%
Consensus Statement
6%
Working Diagnosis
6%
Randomized Controlled Trial
6%
Older Adults
6%
Survival Rate
6%
Sarcopenia
6%
Population Pharmacokinetics
6%
5-year Survival
5%
Newly Diagnosed
5%
Survivors
5%
Preadolescent children
5%
Relapse Risk
5%
Ponte
5%
Improved Survival
5%
Neurobehavior
5%
Peripheral Neuropathy
5%
Bone Mineral Density
5%
Hydrocortisone
5%
PEGylated
5%
Pediatric ALL
5%
Chemotherapy
5%
Risk Stratification
5%
Therapeutic Drug Monitoring
5%
Pediatric Cancer Patients
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Pediatrics
40%
Childhood Cancer
24%
Malignant Neoplasm
22%
Minimal Residual Disease
16%
B Cell
13%
Precursor
12%
Adolescence
11%
Overall Survival
10%
Pediatrics Patient
10%
Acute Myeloid Leukemia
10%
Oncology
9%
Dexamethasone
9%
KMT2A
9%
Leukemia
8%
Pediatric Acute Myeloid Leukemia
8%
Event Free Survival
8%
Randomized Controlled Trial
8%
Survival Rate
7%
Disease
7%
Vincristine
7%
Ganglioneuroblastoma
6%
Neuropathy
6%
Medicine
6%
Neoplasm
6%
High Risk Population
6%
Pediatric Cancer
5%
Maintenance Therapy
5%
Sarcopenia
5%
Risk Stratification
5%